PALI-2108 Posts Positive Phase 1b Crohn's Data, Showing Robust Clinical Signals and Favorable Safety
PALI has more than doubled off its 52-week low of $0.53.
Summary
Palisade Bio announced positive topline data from its Phase 1b clinical study of PALI-2108 in fibrostenotic Crohn's disease. The study demonstrated favorable safety and tolerability, robust pharmacodynamic target engagement, and encouraging early signals of clinical activity, including a 59% reduction in mean fecal calprotectin and a 47.5% reduction in mean SES-CD. This positive clinical update follows the company's recent 10-K filing on March 20, 2026, which reported a significant capital raise in 2025, extending its cash runway through 2028, providing a stronger foundation for advancing its pipeline. The positive Phase 1b data for PALI-2108, a potential first-in-class oral PDE4 inhibitor prodrug targeting both inflammatory and fibrotic components of Crohn's disease, is a significant de-risking event for Palisade Bio. It supports the continued development of a key pipeline asset addressing a high unmet medical need, which could drive substantial value for the company. Investors will now watch for the company's plans for Phase 2 studies in ulcerative colitis and luminal and fibrostenotic Crohn's disease, as well as further details on the clinical development pathway.
At the time of this announcement, PALI was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $295.3M. The 52-week trading range was $0.53 to $2.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.